Third SGLT2 inhibitor to be marketed in Canada

Research | Drugs, medications, sglt2, Type 1 Diabetes, Type 2 Diabetes

Empagliflozin “Jardiance” is the third member of the SGLT2 inhibitor class to be marketed in Canada.  Like the other two members of the class (canagliflozin “Invokana” and dapagliflozin “Forxiga”) it lowers blood sugar and weight by causing wasting of sugar/glucose in the urine.  This results in increased urine volumes in all patients and a tripling of the risk of developing genital thrush infections.  These drugs need to be used with caution in the elderly & those with impaired kidney function.

The recently released EMPA-REG OUTCOME trial in Type 2 diabetic patients at high cardiovascular risk showed striking reductions in all-cause mortality and cardiovascular mortality (NNT = approximately 20).

Translate »